Menopause is a universal midlife transition that profoundly impacts physical, psychological, and sexual wellbeing. In recent years, clinical and public attention has increasingly focused on post-reproductive health, with hormone replacement therapy and targeted symptom management gaining renewed prominence. While a growing array of evidence-based treatment options now exists to address vasomotor, mood, and sexual health concerns, the rapid expansion of therapeutic availability has introduced new clinical challenges. The democratisation of sexual and menopausal health information, though valuable in reducing stigma, has paradoxically decoupled patient expectations from clinical complexity. This review critically examines how digital marketing, social media amplification, and consumer-driven demand increasingly curate diagnostic conclusions before the clinical encounter begins. We demonstrate that these structural pressures, compounded by time-constrained consultations and cognitive heuristics, foster a culture of therapeutic shortcutting – most notably through the premature escalation to testosterone therapy for hypoactive sexual desire disorder. By synthesising evidence on clinical inertia, commercial determinants of health, and diagnostic attribution bias, we argue that current practice frequently bypasses rigorous biopsychosocial assessment, reducing multifactorial symptoms to simplistic hormonal narratives. We contextualise this trend within the regulatory precedent of the mid-urethral tape controversy, warning that unchecked diagnostic expansion risks triggering a blunt-instrument regulatory overcorrection that would indiscriminately restrict access to evidence-based therapies. Ultimately, we advocate for a deliberate return to ethical, humanistic gatekeeping. Clinicians must reclaim the consultation as a deliberative, evidence-based encounter: treating the patient not as a product of commercial demand, but as a whole person navigating a complex physiological and psychosocial transition.